Form 4: Cogent Biosciences Director Matthew Ros Acquires Stock Options

Director Matthew Ros acquired 44,700 stock options in Cogent Biosciences, Inc. on June 5, 2024.

Summary

• On June 5, 2024, Matthew Ros, a director of Cogent Biosciences, Inc., acquired 44,700 stock options.
• The options have an exercise price of $8.92.
• The options vest fully on the earlier of the first anniversary of the grant date or the date of the 2025 Annual Meeting of Stockholders.
• The options expire on June 5, 2034.
• Following the transaction, Ros directly owns 44,700 derivative securities.

Sentiment

Score: 6

Explanation: The sentiment is neutral. It's a standard Form 4 filing indicating a director's acquisition of stock options, which is neither overtly positive nor negative.

Positives

• The acquisition of stock options by a director could be seen as a positive sign, indicating confidence in the company's future performance.

Industry Context

Form 4 filings are a routine part of corporate governance, providing transparency into the transactions of company insiders. This filing indicates a director's acquisition of stock options, which is a common form of executive compensation.

Stakeholder Impact

• Shareholders may view the director's acquisition of stock options as a positive sign, aligning the director's interests with those of the shareholders.

Key Dates